SZSE:002900 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SZSE:002900 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Harbin Medisan Pharmaceutical Co's Total Liabilities for the quarter that ended in Sep. 2024 was ¥1,409 Mil.
Harbin Medisan Pharmaceutical Co's quarterly Total Liabilities declined from Mar. 2024 (¥1,453.69 Mil) to Jun. 2024 (¥1,403.56 Mil) but then increased from Jun. 2024 (¥1,403.56 Mil) to Sep. 2024 (¥1,409.30 Mil).
Harbin Medisan Pharmaceutical Co's annual Total Liabilities increased from Dec. 2021 (¥949.04 Mil) to Dec. 2022 (¥1,225.47 Mil) and increased from Dec. 2022 (¥1,225.47 Mil) to Dec. 2023 (¥1,294.76 Mil).
The historical data trend for Harbin Medisan Pharmaceutical Co's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harbin Medisan Pharmaceutical Co Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Total Liabilities | Get a 7-Day Free Trial | 820.44 | 712.76 | 949.04 | 1,225.47 | 1,294.76 |
Harbin Medisan Pharmaceutical Co Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Total Liabilities | Get a 7-Day Free Trial | 1,301.62 | 1,294.76 | 1,453.69 | 1,403.56 | 1,409.30 |
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Harbin Medisan Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as
Total Liabilities | = | Total Current Liabilities | + | Total Noncurrent Liabilities | ||
= | Total Current Liabilities | + | (Long-Term Debt & Capital Lease Obligation | + | Other Long-Term Liabilities | |
= | 845.034 | + | (238.159 | + | 211.567 | |
+ | NonCurrent Deferred Liabilities | + | PensionAndRetirementBenefit) | |||
+ | 0 | + | 0) | |||
= | 1,295 |
Total Liabilities | = | Total Assets (A: Dec. 2023 ) | - | Total Equity (A: Dec. 2023 ) |
= | 3442.984 | - | 2148.224 | |
= | 1,295 |
Harbin Medisan Pharmaceutical Co's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as
Total Liabilities | = | Total Current Liabilities | + | Total Noncurrent Liabilities | ||
= | Total Current Liabilities | + | (Long-Term Debt & Capital Lease Obligation | + | Other Long-Term Liabilities | |
= | 1071.686 | + | (131.344 | + | 206.265 | |
+ | NonCurrent Deferred Liabilities | + | PensionAndRetirementBenefit) | |||
+ | 0 | + | 0) | |||
= | 1,409 |
Total Liabilities | = | Total Assets (Q: Sep. 2024 ) | - | Total Equity (Q: Sep. 2024 ) |
= | 3555.039 | - | 2145.744 | |
= | 1,409 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Harbin Medisan Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.
Fan Qing Ji | Executives | |
Zhao Qing Fu | Directors, Directors, and Executives | |
Liang Yan Fei | Directors, executives | |
Yao Fa Xiang | Executives | |
Wang Ming Xin | Executives |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.